Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P09012

UPID:
SNRPA_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P09012

BACKGROUND:
The U1 small nuclear ribonucleoprotein A is integral to the spliceosomal U1 snRNP, crucial for pre-mRNA 5' splice-site recognition and spliceosome assembly. It is the first snRNP to interact with pre-mRNA, a step necessary for further snRNP binding and splicing execution. U1 snRNP A's affinity for stem loop II of U1 snRNA and its potential role in pre-mRNA splicing and polyadenylation underscore its significance in RNA processing. Its binding preference for the 5'-UGCAC-3' motif on RNAs highlights its specificity in RNA interactions.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of U1 small nuclear ribonucleoprotein A unveils promising avenues for therapeutic intervention, shedding light on its potential in influencing gene expression pathways and advancing medical research.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.